Lisa Wilsbacher
Cardiovascular Disease · Chicago, ILNPI 1609889690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,000 of the $2,058 with a category attached, or 97.2%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 98.0% of it on its own, with 2 other manufacturers making up the rest.
Across 4 payments — averaging $514.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Bayer$23
- Amgen$17
Across 3 payments — averaging $19,236 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$53K
- Aytu Biopharma, Inc.$5K
What the payments were for
- Speaking & faculty fees$2,00097%
- Food & beverage$402%
- Education$171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $2,017 |
| Bayer | 1 | $23 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$2,000
How this compares
$2,058 in reported general payments places this provider in the 55th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $109,369 |
| JardianceEmpagliflozin | 28 | $42,818 |
| EntrestoSacubitril/Valsartan | 20 | $34,544 |
| XareltoRivaroxaban | 12 | $19,632 |
| Repatha SureclickEvolocumab | 13 | $16,205 |
| Praluent PenAlirocumab | 20 | $9,695 |
| Metoprolol Succinate | 200 | $3,543 |
| Rosuvastatin Calcium | 96 | $1,816 |
| Ezetimibe | 38 | $1,784 |
| Atorvastatin Calcium | 149 | $1,373 |
| Bumetanide | 36 | $1,297 |
| Losartan Potassium | 91 | $940 |
| Carvedilol | 60 | $674 |
| Amlodipine Besylate | 85 | $664 |
| ClopidogrelClopidogrel Bisulfate | 35 | $360 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chicago
- Sandeep NathanChicago$892K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
- Sanjiv ShahChicago$246K
- Raja MutharasanChicago$146K
- Nitasha SarswatChicago$140K
- Evan SteinChicago$121K
- Dan FintelChicago$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.